Devastating Funding Proposal Undermines the Global Fight Against AIDS by Coco Jervis A sense of disbelief washed over the global AIDS community last month when President Obama unveiled his fiscal year 2013 budget proposal to cut $563 million from the…
Merck’s Cavalier Attitude Toward the Welfare of HIV/HCV-Coinfected Patients by Tracy Swan In places where access to antiretroviral therapy is widespread, people living with HIV are now dying from a common and curable coinfection: hepatitis C virus (HCV). HIV increases…
by Richard Jefferys In the earliest days after the discovery of HIV in the mid-1980s, uncertainty reigned regarding how the immune system responded to the virus. Initially, it was thought that the time between HIV infection and the development of…
Reforming NIH AIDS Research, Boosting the Budget, and Revitalizing the Basic Science of HIV Infection by Mark Harrington On January 22, 2012, the Treatment Action Group marked its twentieth anniversary. Over the past two decades, we have helped to accelerate…
Broad, Brilliantly Coordinated Offensive Brings Sneaky Concession From Illinois' Rep. Porter Threats 'Far From Over' When the Republicans took charge of Congress in 1994 and liberal stalwarts like Ann Richards of Texas and Mario Cuomo of New York went down…
A Look Back at an Extraordinary Year for Basic and Clinical Research on AIDS -- and the Questions Raised Additional Surprises Expected The year 1996 witnessed seismic developments in AIDS research. On many fronts -- the basic and the clinical,…
Dr. Robert Schooley on HIV Eradication At the opening ceremony of the Third Congress on Drug Therapy in HIV Infection last month in Birmingham, England, long-time AIDS researcher and chair of the NIAID's AIDS Clinical Trials Group (ACTG), Dr. Robert…
Effect of ddI on Ganciclovir May Explain Disparity Between Two Prophylaxis Studies And CMV PCR Makes its Debut Readers of TAGline are asked to harken back to the duelling ganciclovir studies unveiled this past winter (see the March TAGline, vol.…
Flurry of Discoveries in Multiple Labs Leads to Identification of HIV's Second Receptor -- And New Therapeutic Target The Good, the Bad, the Ugly For nearly a decade Jay Levy, the crotchety virologist at the University of California in San…